Clinical Trials
6 trialsOTHER × Leukemia, Lymphocytic, Chronic, B-Cell × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00611351 2023-10-23
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Phase 2 Completed
NCT01269385 2020-06-23
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 1/2 Completed
NCT00949052 2018-08-16
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Vanderbilt-Ingram Cancer Center
Terminated
NCT00049504 2017-05-17
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01045928 2015-11-26
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00957736 2013-05-14
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Terminated